OTIC - Otonomy Stock Price, News & Analysis

$5.20 -0.17 (-3.17 %)
(As of 11/23/2017 08:01 AM ET)
Previous Close$5.38
Today's Range$5.15 - $5.42
52-Week Range$2.80 - $21.15
Volume603,400 shs
Average Volume820,651 shs
Market Capitalization$163.06 million
P/E RatioN/A
Dividend YieldN/A
Beta2.81

About Otonomy (NASDAQ:OTIC)

Otonomy logoOtonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company's product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase. OTO-104 is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere's disease and other inner ear conditions. OTO-311 is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus. It also has various other product candidates, which target sensorinerual hearing loss, including age-related hearing loss, also known as presbycusis.


Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OTIC
CUSIPN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio13.02%
Quick Ratio12.91%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$680,000.00
Price / Sales232.01
Cash FlowN/A
Price / CashN/A
Book Value$4.37 per share
Price / Book1.19

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($3.23)
Net Income$-110,580,000.00
Net Margins-7,899.03%
Return on Equity-60.74%
Return on Assets-56.22%

Miscellaneous

Employees139
Outstanding Shares30,340,000

Frequently Asked Questions for Otonomy (NASDAQ:OTIC)

What is Otonomy's stock symbol?

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

How were Otonomy's earnings last quarter?

Otonomy, Inc. (NASDAQ:OTIC) released its earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.84) by $0.15. The biopharmaceutical company had revenue of $0.28 million for the quarter, compared to the consensus estimate of $0.43 million. Otonomy had a negative return on equity of 60.74% and a negative net margin of 7,899.03%. Otonomy's revenue for the quarter was down 12.8% compared to the same quarter last year. View Otonomy's Earnings History.

Where is Otonomy's stock going? Where will Otonomy's stock price be in 2017?

4 equities research analysts have issued 12 month target prices for Otonomy's shares. Their forecasts range from $8.00 to $15.00. On average, they expect Otonomy's share price to reach $10.00 in the next twelve months. View Analyst Ratings for Otonomy.

Are investors shorting Otonomy?

Otonomy saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 1,429,693 shares, an increase of 42.8% from the October 13th total of 1,001,269 shares. Based on an average daily trading volume, of 710,188 shares, the short-interest ratio is presently 2.0 days. Currently, 5.6% of the company's stock are sold short.

Who are some of Otonomy's key competitors?

Who are Otonomy's key executives?

Otonomy's management team includes the folowing people:

  • Jay Lichter Ph.D., Independent Chairman of the Board
  • David A. Weber Ph.D., President, Chief Executive Officer, Director
  • Paul E. Cayer, Chief Financial and Business Officer
  • Robert Michael Savel II, Chief Technical Officer
  • Kathie M. Bishop Ph.D., Chief Scientific Officer
  • Eric J. Loumeau, Chief Compliance Officer, General Counsel, Secretary
  • Dean Hakanson M.D., Chief Medical Officer
  • Vickie L. Capps, Independent Director
  • Iain R. McGill, Independent Director
  • George J. Morrow, Independent Director

Who owns Otonomy stock?

Otonomy's stock is owned by a number of of institutional and retail investors. Top institutional investors include Orbimed Advisors LLC (2.12%), Bank of New York Mellon Corp (1.97%), Dimensional Fund Advisors LP (1.44%), Alpine Associates Management Inc. (0.81%), Dynamic Technology Lab Private Ltd (0.27%) and Los Angeles Capital Management & Equity Research Inc. (0.13%). Company insiders that own Otonomy stock include Carl Lebel, Chau Quang Khuong, David Allen Weber, Eric J Loumeau, Orbimed Advisors Llc, Paul E Cayer and Robert Michael Savel II. View Institutional Ownership Trends for Otonomy.

Who sold Otonomy stock? Who is selling Otonomy stock?

Otonomy's stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC and Granite Investment Partners LLC. View Insider Buying and Selling for Otonomy.

Who bought Otonomy stock? Who is buying Otonomy stock?

Otonomy's stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Alpine Associates Management Inc., Dynamic Technology Lab Private Ltd, Los Angeles Capital Management & Equity Research Inc., Lakeview Capital Partners LLC and Dimensional Fund Advisors LP. View Insider Buying and Selling for Otonomy.

How do I buy Otonomy stock?

Shares of Otonomy can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Otonomy's stock price today?

One share of Otonomy stock can currently be purchased for approximately $5.20.

How big of a company is Otonomy?

Otonomy has a market capitalization of $163.06 million and generates $680,000.00 in revenue each year. The biopharmaceutical company earns $-110,580,000.00 in net income (profit) each year or ($3.23) on an earnings per share basis. Otonomy employs 139 workers across the globe.

How can I contact Otonomy?

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected]


MarketBeat Community Rating for Otonomy (OTIC)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  146 (Vote Outperform)
Underperform Votes:  100 (Vote Underperform)
Total Votes:  246
MarketBeat's community ratings are surveys of what our community members think about Otonomy and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Otonomy (NASDAQ:OTIC)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 2 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $10.00 (92.31% upside)

Consensus Price Target History for Otonomy (NASDAQ:OTIC)

Price Target History for Otonomy (NASDAQ:OTIC)

Analysts' Ratings History for Otonomy (NASDAQ:OTIC)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/10/2017Piper Jaffray CompaniesReiterated RatingHold$8.00N/AView Rating Details
8/31/2017Cowen and CompanyReiterated RatingOutperform$55.00 -> $9.00LowView Rating Details
8/31/2017SunTrust Banks, Inc.Reiterated RatingBuy$45.00 -> $15.00HighView Rating Details
8/30/2017J P Morgan Chase & CoDowngradeOverweight -> Neutral$28.00 -> $8.00HighView Rating Details
5/26/2016WallachBeth CapitalInitiated CoverageBuy$29.00N/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for Otonomy (NASDAQ:OTIC)

Earnings by Quarter for Otonomy (NASDAQ:OTIC)

Earnings History by Quarter for Otonomy (NASDAQ OTIC)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.84)($0.69)$0.43 million$0.28 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.80)($0.77)$0.43 million$0.33 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.84)($0.89)$0.50 million$0.36 millionViewListenView Earnings Details
3/2/2017Q4 2016($0.93)($0.88)$0.49 million$0.27 millionViewListenView Earnings Details
3/7/2016Q4($0.95)($0.87)ViewListenView Earnings Details
11/10/2015Q315($0.83)($0.57)ViewN/AView Earnings Details
8/12/2015Q116($0.67)($0.52)ViewN/AView Earnings Details
5/12/2015Q115($0.53)($0.52)ViewN/AView Earnings Details
3/18/2015Q415($0.64)($0.46)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Otonomy (NASDAQ:OTIC)
2017 EPS Consensus Estimate: ($0.74)
2018 EPS Consensus Estimate: ($3.14)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q4 20171($0.74)($0.74)($0.74)
Q1 20181($0.74)($0.74)($0.74)
Q2 20181($0.78)($0.78)($0.78)
Q3 20181($0.81)($0.81)($0.81)
Q4 20181($0.81)($0.81)($0.81)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Otonomy (NASDAQ:OTIC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Otonomy (NASDAQ OTIC)

Insider Ownership Percentage: 12.70%
Institutional Ownership Percentage: 66.14%
Insider Trades by Quarter for Otonomy (NASDAQ:OTIC)
Institutional Ownership by Quarter for Otonomy (NASDAQ:OTIC)

Insider Trades by Quarter for Otonomy (NASDAQ OTIC)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/26/2017Eric J. LoumeauInsiderSell3,522$18.59$65,473.98View SEC Filing  
11/21/2016Carl LebelInsiderSell10,625$18.07$191,993.75View SEC Filing  
12/21/2015Carl LebelinsiderSell21,250$28.04$595,850.00View SEC Filing  
12/17/2015Paul E. CayerinsiderSell3,000$29.70$89,100.00View SEC Filing  
12/15/2015David Allen WeberCEOSell5,208$27.25$141,918.00View SEC Filing  
12/14/2015Robert Michael Savel IIinsiderSell5,000$26.00$130,000.00View SEC Filing  
11/30/2015Chau Quang KhuongDirectorSell67,106$28.93$1,941,376.58View SEC Filing  
11/24/2015Orbimed Advisors LlcDirectorSell200,800$28.56$5,734,848.00View SEC Filing  
11/19/2015Chau Quang KhuongDirectorSell138,398$28.62$3,960,950.76View SEC Filing  
11/17/2015Paul E. CayerinsiderSell3,000$28.69$86,070.00View SEC Filing  
11/16/2015David Allen WeberCEOSell5,208$28.57$148,792.56View SEC Filing  
11/13/2015David Allen WeberCEOSell10,416$30.95$322,375.20View SEC Filing  
11/11/2015David Allen WeberCEOSell5,208$24.95$129,939.60View SEC Filing  
11/11/2015Paul E. CayerCFOSell3,000$24.95$74,850.00View SEC Filing  
9/21/2015Carl LebelinsiderSell21,250$24.36$517,650.00View SEC Filing  
9/17/2015Paul E. CayerCFOSell3,000$24.95$74,850.00View SEC Filing  
9/15/2015David Allen WeberCEOSell5,216$24.95$130,139.20View SEC Filing  
9/14/2015Robert Michael Savel IIinsiderSell5,000$23.98$119,900.00View SEC Filing  
6/15/2015Robert Michael Savel IIInsiderSell25,000$23.73$593,250.00View SEC Filing  
8/19/2014A/S NovoInsiderBuy15,690$15.50$243,195.00View SEC Filing  
8/18/2014A/S NovoInsiderBuy171,875$16.00$2,750,000.00View SEC Filing  
8/18/2014Jay LichterDirectorSell50,001$16.00$800,016.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Otonomy (NASDAQ OTIC)

Source:
DateHeadline
Otonomy (OTIC) vs. The Competition Head-To-Head ComparisonOtonomy (OTIC) vs. The Competition Head-To-Head Comparison
www.americanbankingnews.com - November 20 at 11:19 AM
Otonomy Sees Unusually High Options Volume (OTIC)Otonomy Sees Unusually High Options Volume (OTIC)
www.americanbankingnews.com - November 18 at 2:28 AM
Otonomy, Inc. (OTIC) Upgraded by Zacks Investment Research to BuyOtonomy, Inc. (OTIC) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - November 14 at 6:30 AM
Otonomy, Inc. (OTIC) Given Consensus Recommendation of "Hold" by BrokeragesOtonomy, Inc. (OTIC) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 14 at 1:50 AM
Equities Analysts Issue Forecasts for Otonomy, Inc.s FY2017 Earnings (OTIC)Equities Analysts Issue Forecasts for Otonomy, Inc.'s FY2017 Earnings (OTIC)
www.americanbankingnews.com - November 13 at 2:36 AM
Otonomy, Inc. (OTIC) Short Interest UpdateOtonomy, Inc. (OTIC) Short Interest Update
www.americanbankingnews.com - November 13 at 2:32 AM
Piper Jaffray Companies Reiterates Hold Rating for Otonomy, Inc. (OTIC)Piper Jaffray Companies Reiterates Hold Rating for Otonomy, Inc. (OTIC)
www.americanbankingnews.com - November 11 at 9:42 AM
Otonomy, Inc. (OTIC) Expected to Post Quarterly Sales of $680,000.00Otonomy, Inc. (OTIC) Expected to Post Quarterly Sales of $680,000.00
www.americanbankingnews.com - November 11 at 4:39 AM
Otonomy Rips 90% After Menieres Disease Drug Achieves Primary EndpointOtonomy Rips 90% After Meniere's Disease Drug Achieves Primary Endpoint
www.benzinga.com - November 10 at 7:52 PM
Otonomy Inc. (OTIC) Is Rising On Phase 3 Study ResultsOtonomy Inc. (OTIC) Is Rising On Phase 3 Study Results
www.rttnews.com - November 10 at 7:52 PM
Today’s Research Reports on Stocks to Watch: Marinus Pharmaceuticals, Inc. and Otonomy, Inc.Today’s Research Reports on Stocks to Watch: Marinus Pharmaceuticals, Inc. and Otonomy, Inc.
finance.yahoo.com - November 10 at 2:51 PM
Otonomy Gets Another Vote of Confidence from SunTrustOtonomy Gets Another Vote of Confidence from SunTrust
finance.yahoo.com - November 10 at 2:51 PM
Otonomy, Inc. (OTIC) Expected to Announce Earnings of -$0.76 Per ShareOtonomy, Inc. (OTIC) Expected to Announce Earnings of -$0.76 Per Share
www.americanbankingnews.com - November 9 at 9:22 PM
Otonomy (OTIC) Says AVERTS-2 Phase 3 Trial of OTIVIDEX Achieved Primary Endpoint - StreetInsider.comOtonomy (OTIC) Says AVERTS-2 Phase 3 Trial of OTIVIDEX Achieved Primary Endpoint - StreetInsider.com
www.streetinsider.com - November 9 at 3:26 PM
Otonomy, Inc. (OTIC) Announces  Earnings ResultsOtonomy, Inc. (OTIC) Announces Earnings Results
www.americanbankingnews.com - November 9 at 1:14 PM
Otonomy (OTIC) Says AVERTS-2 Phase 3 Trial of OTIVIDEX Achieved Primary EndpointOtonomy (OTIC) Says AVERTS-2 Phase 3 Trial of OTIVIDEX Achieved Primary Endpoint
www.streetinsider.com - November 9 at 10:53 AM
Otonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX™ in Patients with Ménières DiseaseOtonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX™ in Patients with Ménière's Disease
finance.yahoo.com - November 9 at 10:52 AM
Otonomy Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateOtonomy Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 9 at 10:52 AM
Otonomy reports 3Q lossOtonomy reports 3Q loss
finance.yahoo.com - November 9 at 10:52 AM
Why Otonomy Shares Are SkyrocketingWhy Otonomy Shares Are Skyrocketing
finance.yahoo.com - November 9 at 10:52 AM
Sage Skyrockets on Postpartum Depression Drug Studies Data -- Biotech MoversSage Skyrockets on Postpartum Depression Drug Studies Data -- Biotech Movers
finance.yahoo.com - November 9 at 10:52 AM
Otonomy Inc (OTIC) Sparks Optimism Among Investors; Here’s WhyOtonomy Inc (OTIC) Sparks Optimism Among Investors; Here’s Why
finance.yahoo.com - November 9 at 10:51 AM
ETFs with exposure to Otonomy, Inc. : November 6, 2017ETFs with exposure to Otonomy, Inc. : November 6, 2017
finance.yahoo.com - November 7 at 8:22 AM
Comparing Otonomy (OTIC) & Its PeersComparing Otonomy (OTIC) & Its Peers
www.americanbankingnews.com - November 5 at 11:14 AM
Otonomy to Report Third Quarter 2017 Financial Results and Provide Corporate UpdateOtonomy to Report Third Quarter 2017 Financial Results and Provide Corporate Update
finance.yahoo.com - November 2 at 7:25 AM
Otonomy Inc (OTIC) Scheduled to Post Quarterly Earnings on WednesdayOtonomy Inc (OTIC) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 25 at 8:02 AM
Otonomy, Inc. (OTIC) Receives Average Recommendation of "Hold" from AnalystsOtonomy, Inc. (OTIC) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 20 at 2:48 AM
Bottom Fishing With Cash-Rich BiotechsBottom Fishing With Cash-Rich Biotechs
finance.yahoo.com - October 3 at 2:14 AM
Otonomy, Inc. (OTIC) Short Interest Down 40.6% in SeptemberOtonomy, Inc. (OTIC) Short Interest Down 40.6% in September
www.americanbankingnews.com - September 30 at 3:26 AM
Otonomy, Inc. (OTIC) Receives Consensus Recommendation of "Hold" from AnalystsOtonomy, Inc. (OTIC) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - September 25 at 2:38 AM
$450,000.00 in Sales Expected for Otonomy, Inc. (OTIC) This Quarter$450,000.00 in Sales Expected for Otonomy, Inc. (OTIC) This Quarter
www.americanbankingnews.com - September 15 at 5:20 AM
-$0.76 EPS Expected for Otonomy, Inc. (OTIC) This Quarter-$0.76 EPS Expected for Otonomy, Inc. (OTIC) This Quarter
www.americanbankingnews.com - September 13 at 4:28 PM
Otonomy Provides Business and Financial UpdateOtonomy Provides Business and Financial Update
finance.yahoo.com - September 13 at 7:33 AM
Otonomy Fails Phase III - Best To AvoidOtonomy Fails Phase III - Best To Avoid
seekingalpha.com - September 6 at 7:19 AM
Otonomy Sees Unusually Large Options Volume (OTIC)Otonomy Sees Unusually Large Options Volume (OTIC)
www.americanbankingnews.com - September 3 at 1:26 AM
ETFs with exposure to Otonomy, Inc. : August 31, 2017ETFs with exposure to Otonomy, Inc. : August 31, 2017
finance.yahoo.com - September 1 at 6:58 AM
Otonomy, Inc. (OTIC) Earns "Outperform" Rating from Cowen and CompanyOtonomy, Inc. (OTIC) Earns "Outperform" Rating from Cowen and Company
www.americanbankingnews.com - August 31 at 6:20 PM
Otonomy, Inc. (OTIC) Given Average Rating of "Hold" by BrokeragesOtonomy, Inc. (OTIC) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - August 31 at 11:00 AM
Otonomy, Inc. (OTIC) Rating Reiterated by SunTrust Banks, Inc.Otonomy, Inc. (OTIC) Rating Reiterated by SunTrust Banks, Inc.
www.americanbankingnews.com - August 31 at 9:50 AM
Why Otonomy Shares Are Getting Absolutely CrushedWhy Otonomy Shares Are Getting Absolutely Crushed
finance.yahoo.com - August 31 at 8:24 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Otonomy, Inc.SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Otonomy, Inc.
finance.yahoo.com - August 31 at 8:24 AM
The Long and Short of Biotech StocksThe Long and Short of Biotech Stocks
finance.yahoo.com - August 31 at 8:24 AM
Here's Why the Market Is Eviscerating Otonomy Inc. Stock TodayHere's Why the Market Is Eviscerating Otonomy Inc. Stock Today
finance.yahoo.com - August 31 at 8:24 AM
OTONOMY INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Otonomy, Inc. To Contact The FirmOTONOMY INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Otonomy, Inc. To Contact The Firm
finance.yahoo.com - August 31 at 8:24 AM
Biotech Nears Zero On Dizzying Plunge After Failed Vertigo TrialBiotech Nears Zero On Dizzying Plunge After Failed Vertigo Trial
finance.yahoo.com - August 31 at 8:24 AM
Why Otonomy Inc (OTIC), Dycom Industries, Inc. (DY) and Mondelez International Inc (MDLZ) Are 3 of Today’s Worst StocksWhy Otonomy Inc (OTIC), Dycom Industries, Inc. (DY) and Mondelez International Inc (MDLZ) Are 3 of Today’s Worst Stocks
investorplace.com - August 30 at 5:07 PM
Otonomy, Inc. (OTIC) Stock Rating Lowered by Piper Jaffray CompaniesOtonomy, Inc. (OTIC) Stock Rating Lowered by Piper Jaffray Companies
www.americanbankingnews.com - August 30 at 1:14 PM
Otonomy, Inc. (OTIC) Downgraded to "Neutral" at J P Morgan Chase & CoOtonomy, Inc. (OTIC) Downgraded to "Neutral" at J P Morgan Chase & Co
www.americanbankingnews.com - August 30 at 10:42 AM
Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX™ in Patients with Ménières DiseaseOtonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX™ in Patients with Ménière's Disease
finance.yahoo.com - August 30 at 7:40 AM
Otonomys ear disease drug fails late-stage studyOtonomy's ear disease drug fails late-stage study
finance.yahoo.com - August 30 at 7:40 AM

Social Media

Financials

Chart

Otonomy (NASDAQ OTIC) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.